P
PureTech Health plc (PTCHF)
PNK – Real Time Price. Currency in USD
1.65
+0.09 (5.50%)
Market open: Sep 8, 2026, 4:00 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
PNK – Real Time Price. Currency in USD
1.65
+0.09 (5.50%)
Market open: Sep 8, 2026, 4:00 PM EDT
PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. It is developing LYT-100, a Phase 3-ready therapeutic candidate with the potential to establish a new standard of care (SOC) for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases and LYT-200, a fully human IgG4 monoclonal antibody. The company also develops SPT-300, a Glyphed oral prodrug of allopregnanolone for the treatment of anxious depression; and delivers transformative medicines for patients with psychiatric and neurological conditions. In addition, the company develops hydrogels to enable the oral administration of peptide therapeutics in preclinical development and oral therapies based on defined bacterial consortia that is in phase 3 clinical stage. PureTech Health plc was incorporated in 2015 and is based in Boston, Massachusetts.
| Name | Position |
|---|---|
| Dr. David R. Elmaleh Ph.D. | Co-Founder & Senior Advisor |
| Dr. Eric Elenko Ph.D. | Co-Founder & President |
| Dr. Robert S. Langer Jr., Ph.D., ScD | Co-Founder & Non-Executive Director |
| Mr. Charles Sherwood III, J.D., Ph.D. | COO, General Counsel & Company Secretary |
| Mr. Michael Inbar CPA, M.B.A. | Chief Accounting Officer |
| Mr. Robert Lyne J.D., L.L.B. | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-05-22 | F-6 POS | e665452_f6pos-puretech.htm |
| 2026-05-21 | 15F-12B | d73218d15f12b.htm |
| 2026-05-11 | 25 | d54446d25.htm |
| 2026-05-01 | 6-K | d22215d6k.htm |
| 2026-04-29 | 6-K | d37980d6k.htm |
| 2025-12-18 | 6-K | d76650d6k.htm |
| 2025-12-10 | 6-K | d933871d6k.htm |
| 2025-08-28 | 6-K | a6-kformhy2025hyonly.htm |
| 2025-07-16 | 6-K | d863451d6k.htm |
| 2025-07-08 | 6-K | d48616d6k.htm |
| Ms. Aleksandra Filipovic M.D., Ph.D. | Head of Oncology |
| Ms. Allison Mead Talbot | Senior VP of Communications & Head of Investor Relations |
| Ms. Joy Bauer M.S., RDN | Chief Nutrition Officer |
| Ms. Lauren A. White M.B.A. | Chief Financial Officer |